Kingmed Diagnostics(SH:603882) ZHONGTAI SECURITIES·2025-11-04 06:26Investment Rating - The investment rating for the company is "Buy" (maintained) [3][15] Core Views - The company is undergoing a transformation that is beginning to show results, with a focus on optimizing its product portfolio and enhancing the value of data elements [3][4] - The company reported a revenue of 45.38 billion yuan for the first three quarters of 2025, a year-on-year decline of 19.23%, with a net profit attributable to shareholders of -0.80 billion yuan [4][5] - The third quarter of 2025 showed signs of recovery, with revenue of 15.41 billion yuan, a year-on-year decline of 11.32%, and a net profit of 0.05 billion yuan, reflecting a 24.08% increase year-on-year [5][6] Financial Performance - The company’s revenue forecast for 2025-2027 is projected at 61.65 billion, 66.41 billion, and 71.55 billion yuan, with respective growth rates of -14%, 8%, and 8% [6][4] - The net profit attributable to shareholders is expected to be 0.10 billion, 4.41 billion, and 4.86 billion yuan for the same period, indicating a significant recovery [6][4] - The company’s current stock price corresponds to a P/E ratio of 1356, 32, and 29 for 2025-2027, reflecting its leading position in the industry and ongoing advancements in data intelligence [6][4] Operational Insights - The company has expanded its customer base and optimized its product offerings, leading to a 53.8% year-on-year increase in revenue from its public welfare product system [6][5] - The integration of AI applications has improved diagnostic efficiency, with the "Xiao Yu Yi" clinical assistant achieving over 599 million cumulative calls and 140,000 monthly active users by the third quarter of 2025 [6][5] - The company has registered six specialized disease datasets and launched 21 data products on various data trading platforms, establishing long-term data cooperation with multiple clients [6][5]